C

Coya Therapeutics Inc
NASDAQ:COYA

Watchlist Manager
Coya Therapeutics Inc
NASDAQ:COYA
Watchlist
Price: 5.41 USD -4.59% Market Closed
Market Cap: 90.5m USD

EV/EBITDA
Enterprise Value to EBITDA

-2.7
Current
-3.7
Median
5.4
Industry
Higher than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-2.7
=
Enterprise Value
60.7m USD
/
EBITDA
-22.6m USD
EBITDA Growth EV/EBITDA to Growth
US
C
Coya Therapeutics Inc
NASDAQ:COYA
Average EV/EBITDA: 15.4
Negative Multiple: -2.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -193 713.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
17.1
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
17.7
10%
1.8
US
Gilead Sciences Inc
NASDAQ:GILD
10.4
6%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -583.2 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
20
17%
1.2
AU
CSL Ltd
ASX:CSL
14.2
10%
1.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.9
9%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -463.1 N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.9 N/A N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
N/A
2-Years Forward
EV/EBITDA
N/A
3-Years Forward
EV/EBITDA
N/A